{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/cyproterone",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949167",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949167_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aprepitant\" outputclass=\"int-drug\">Aprepitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aprepitant   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949168",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949168_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949169",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949169_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949170",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949170_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Efavirenz   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949171",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949171_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eslicarbazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949172",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949172_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosaprepitant\" outputclass=\"int-drug\">Fosaprepitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosaprepitant   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosaprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949173",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949173_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949174",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949174_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"griseofulvin\" outputclass=\"int-drug\">Griseofulvin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Griseofulvin   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Griseofulvin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949175",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949175_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"modafinil\" outputclass=\"int-drug\">Modafinil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Modafinil   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Modafinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949176",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949176_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nevirapine\" outputclass=\"int-drug\">Nevirapine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nevirapine   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nevirapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949177",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949177_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxcarbazepine\" outputclass=\"int-drug\">Oxcarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxcarbazepine   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxcarbazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949178",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949178_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"perampanel\" outputclass=\"int-drug\">Perampanel</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Perampanel   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perampanel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949179",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949179_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949180",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949180_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949181",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949181_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949182",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949182_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifabutin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949183",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949183_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949184",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949184_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949185",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949185_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rufinamide\" outputclass=\"int-drug\">Rufinamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rufinamide   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rufinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949186",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyproterone#bnf_i1643857949186_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"topiramate\" outputclass=\"int-drug\">Topiramate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-heading-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Topiramate   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topiramate</title>"
					}
				}
			],
			"hasSearchLabel": " Cyproterone  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/cyproterone.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Cyproterone </title>"
			},
			"rdfs:label": "cyproterone"
		}
	]
}